Leukemia drug appears to stop early stage MS

By Michael Kahn

LONDON (Reuters) - A drug developed to fight leukemia appears to stop multiple sclerosis in its early stages and restore lost function to patients, British researchers said on Wednesday.

The three-year study of Bayer AG and Genzyme Corp’s alemtuzumab for the first time show long-term improvement in disability, Alasdair Cole, a neurologist at the University of Cambridge, said in a telephone interview.

The drug, made under the brand name Campath, appears to regenerate brain cells and reverse the effects of relapsing-remitting multiple sclerosis, the researchers found.

“This is the first drug that has shown that people’s disability at the end of a period of time has actually improved,” Cole, who helped lead the study, said. “That is really encouraging for people with the disease.”

Multiple sclerosis is a disease in which the immune system mistakenly attacks and damages the myelin sheath that protects nerve cells. It affects 2.5 million people globally and can cause symptoms ranging from vague tingling to blindness and paralysis.

Standard treatments using a protein known as recombinant interferon beta include Biogen Idec Inc’s Avonex, the newer treatment Tysabri, developed by Biogen Idec and Elan, and Merck KGaA’s Rebif.

The study compared alemtuzumab to Rebif in 300 men and women with early stage MS, marked by flare-ups of numbness, vision loss and other problems that can last weeks or months.

Campath reduced the number of attacks by 74 percent compared to Rebif and reduced the risk of disability worsening by 71 percent.  Continued…


Related Posts:

NEW YORK (Reuters) - Biogen Idec Inc said on Monday it notified regulators of a new case of a potentially deadly brain disease in a patient being treated with its Tysabri multiple sclerosis drug, the fourth such case reported globally this year. The latest case of the brain infection, known as progressive multifocal leukoencephalopathy (PML), was

Full Post: Biogen says new brain infection linked to Tysabri

WASHINGTON (Reuters) - The popular multiple sclerosis drug Tysabri appears to promote a rare brain infection by suppressing immune system cells in the brain, researchers said on Tuesday. The researchers, who conducted an autopsy on an MS patient who died while taking the drug, said it may be possible to make the drug safer by giving

Full Post: MS drug Tysabri may promote brain infection: study

By Toni Clarke BOSTON (Reuters) - Biogen Idec Inc said on Friday that a multiple sclerosis patient who had been diagnosed with a rare brain infection while taking its drug Tysabri has died, sending the company’s shares down nearly 3 percent. Biogen and its partner Elan Corp Plc disclosed the case in October. Naomi Aoki, a spokeswoman

Full Post: Biogen says Tysabri PML patient dies in U.S.

CHICAGO (Reuters) - A long-term study of brain scans in multiple sclerosis patients showed only about half of the patients who took the drug interferon beta 1-b got a long-lasting benefit, U.S. researchers said on Monday. Patients in the small, three-year study were treated with the Bayer drug, which is sold under the trade name Betaseron

Full Post: Bayer drug delays MS in half of patients: MRI study

LOS ANGELES (Reuters) - A combination of Genentech Inc’s cancer drug Rituxan and chemotherapy reduces by 41 percent the risk of death or cancer progression, compared with chemotherapy alone, for patients with a common form of leukemia, the company said on Saturday. Results from the pivotal- or final-stage trial found that previously untreated patients given the

Full Post: Genentech drug boosts leukemia patient survival

Site Navigation

Most Read



  • kinwrite.com@gmail.com